CN102763784B - 一种哺乳期母猪配合饲料及其制备方法 - Google Patents
一种哺乳期母猪配合饲料及其制备方法 Download PDFInfo
- Publication number
- CN102763784B CN102763784B CN2012102775284A CN201210277528A CN102763784B CN 102763784 B CN102763784 B CN 102763784B CN 2012102775284 A CN2012102775284 A CN 2012102775284A CN 201210277528 A CN201210277528 A CN 201210277528A CN 102763784 B CN102763784 B CN 102763784B
- Authority
- CN
- China
- Prior art keywords
- sow
- lactation
- sows
- mixed feed
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000006651 lactation Effects 0.000 title claims abstract description 31
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 150000001875 compounds Chemical class 0.000 title abstract description 7
- 239000000463 material Substances 0.000 claims abstract description 22
- 239000007788 liquid Substances 0.000 claims abstract description 21
- 240000008042 Zea mays Species 0.000 claims abstract description 18
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 18
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 18
- 235000005822 corn Nutrition 0.000 claims abstract description 18
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims abstract description 14
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 14
- 241000209140 Triticum Species 0.000 claims abstract description 13
- 235000021307 Triticum Nutrition 0.000 claims abstract description 13
- 108090000790 Enzymes Proteins 0.000 claims abstract description 11
- 102000004190 Enzymes Human genes 0.000 claims abstract description 11
- 229940088598 enzyme Drugs 0.000 claims abstract description 11
- 235000019774 Rice Bran oil Nutrition 0.000 claims abstract description 8
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000004473 Threonine Substances 0.000 claims abstract description 8
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 8
- 239000008165 rice bran oil Substances 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims abstract description 7
- 108010011619 6-Phytase Proteins 0.000 claims abstract description 7
- 235000019743 Choline chloride Nutrition 0.000 claims abstract description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000004472 Lysine Substances 0.000 claims abstract description 7
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 7
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims abstract description 7
- 229960003178 choline chloride Drugs 0.000 claims abstract description 7
- 235000013312 flour Nutrition 0.000 claims abstract description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims abstract description 7
- 235000019341 magnesium sulphate Nutrition 0.000 claims abstract description 7
- 229940085127 phytase Drugs 0.000 claims abstract description 7
- 239000001103 potassium chloride Substances 0.000 claims abstract description 7
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 7
- 238000005303 weighing Methods 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 35
- 244000020518 Carthamus tinctorius Species 0.000 claims description 25
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims description 25
- 239000000654 additive Substances 0.000 claims description 21
- 230000000996 additive effect Effects 0.000 claims description 21
- 244000290970 Tetrapanax papyrifer Species 0.000 claims description 17
- BXMVKQIIJSXIBU-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) diphenyl phosphate Chemical compound O=C1CCC(=O)N1OP(=O)(OC=1C=CC=CC=1)OC1=CC=CC=C1 BXMVKQIIJSXIBU-UHFFFAOYSA-N 0.000 claims description 13
- 239000002994 raw material Substances 0.000 claims description 12
- 239000010231 banlangen Substances 0.000 claims description 11
- 238000000227 grinding Methods 0.000 claims description 11
- 235000019742 Vitamins premix Nutrition 0.000 claims description 10
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 claims description 10
- 241000512259 Ascophyllum nodosum Species 0.000 claims description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
- 239000002245 particle Substances 0.000 claims description 8
- 235000013527 bean curd Nutrition 0.000 claims description 7
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 6
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 6
- 235000006708 antioxidants Nutrition 0.000 claims description 6
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 6
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 6
- 239000004575 stone Substances 0.000 claims description 6
- 239000009636 Huang Qi Substances 0.000 claims description 5
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 4
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 4
- 229910052802 copper Inorganic materials 0.000 claims description 4
- 239000010949 copper Substances 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- 229910052742 iron Inorganic materials 0.000 claims description 4
- 235000019155 vitamin A Nutrition 0.000 claims description 4
- 239000011719 vitamin A Substances 0.000 claims description 4
- 229940045997 vitamin a Drugs 0.000 claims description 4
- 239000011701 zinc Substances 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- 101710130006 Beta-glucanase Proteins 0.000 claims description 3
- 108010059892 Cellulase Proteins 0.000 claims description 3
- 229940106157 cellulase Drugs 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 230000008676 import Effects 0.000 claims description 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 229940055726 pantothenic acid Drugs 0.000 claims description 2
- 235000019161 pantothenic acid Nutrition 0.000 claims description 2
- 239000011713 pantothenic acid Substances 0.000 claims description 2
- 239000011669 selenium Substances 0.000 claims description 2
- 229910052711 selenium Inorganic materials 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 abstract description 14
- 239000008267 milk Substances 0.000 abstract description 14
- 210000004080 milk Anatomy 0.000 abstract description 14
- 235000016709 nutrition Nutrition 0.000 abstract description 10
- 230000035764 nutrition Effects 0.000 abstract description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 3
- 239000011575 calcium Substances 0.000 abstract description 3
- 229910052791 calcium Inorganic materials 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 3
- 235000019629 palatability Nutrition 0.000 abstract description 3
- 102000004506 Blood Proteins Human genes 0.000 abstract 1
- 108010017384 Blood Proteins Proteins 0.000 abstract 1
- 244000068988 Glycine max Species 0.000 abstract 1
- 235000010469 Glycine max Nutrition 0.000 abstract 1
- 235000019738 Limestone Nutrition 0.000 abstract 1
- 235000019764 Soybean Meal Nutrition 0.000 abstract 1
- 239000006028 limestone Substances 0.000 abstract 1
- 230000000474 nursing effect Effects 0.000 abstract 1
- 239000008188 pellet Substances 0.000 abstract 1
- 239000004455 soybean meal Substances 0.000 abstract 1
- 235000013619 trace mineral Nutrition 0.000 abstract 1
- 239000011573 trace mineral Substances 0.000 abstract 1
- 235000013343 vitamin Nutrition 0.000 abstract 1
- 239000011782 vitamin Substances 0.000 abstract 1
- 229940088594 vitamin Drugs 0.000 abstract 1
- 229930003231 vitamin Natural products 0.000 abstract 1
- 150000003722 vitamin derivatives Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 29
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 241000283973 Oryctolagus cuniculus Species 0.000 description 14
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 description 13
- DYQVDISPPLTLLR-HJQYTNQXSA-N Carthamin Natural products CC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@]2(O)C(=C(C=C/3C(=O)C(=C(O)[C@](O)([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C3=O)C(=O)C=Cc5ccc(O)cc5)C(=O)C(=C2O)C(=O)C=Cc6ccc(O)cc6)O DYQVDISPPLTLLR-HJQYTNQXSA-N 0.000 description 13
- 241000282898 Sus scrofa Species 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 13
- 238000004519 manufacturing process Methods 0.000 description 11
- 231100000678 Mycotoxin Toxicity 0.000 description 9
- 150000004676 glycans Chemical class 0.000 description 9
- 239000002636 mycotoxin Substances 0.000 description 9
- 229920001282 polysaccharide Polymers 0.000 description 9
- 239000005017 polysaccharide Substances 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 235000019197 fats Nutrition 0.000 description 7
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 7
- 210000002216 heart Anatomy 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 210000004291 uterus Anatomy 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000004880 Polyuria Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000035619 diuresis Effects 0.000 description 5
- 230000012173 estrus Effects 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000005284 excitation Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 241000411851 herbal medicine Species 0.000 description 4
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
- 210000004165 myocardium Anatomy 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 241000489523 Veratrum Species 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
- 229960005205 prednisolone Drugs 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 244000247747 Coptis groenlandica Species 0.000 description 2
- 235000002991 Coptis groenlandica Nutrition 0.000 description 2
- 235000019750 Crude protein Nutrition 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 229920001543 Laminarin Polymers 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 240000007711 Peperomia pellucida Species 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 241000545442 Radix Species 0.000 description 2
- 241001442514 Schistosomatidae Species 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 229960000796 barbital sodium Drugs 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000004856 capillary permeability Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 2
- 235000005282 vitamin D3 Nutrition 0.000 description 2
- 239000011647 vitamin D3 Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940021056 vitamin d3 Drugs 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 1
- KKAJSJJFBSOMGS-UHFFFAOYSA-N 3,6-diamino-10-methylacridinium chloride Chemical compound [Cl-].C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 KKAJSJJFBSOMGS-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 240000008027 Akebia quinata Species 0.000 description 1
- 235000007756 Akebia quinata Nutrition 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 102000016912 Aldehyde Reductase Human genes 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 241000205585 Aquilegia canadensis Species 0.000 description 1
- 206010003084 Areflexia Diseases 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000754688 Cercaria Species 0.000 description 1
- 241000258920 Chilopoda Species 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000031973 Conjunctivitis infective Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 101100276976 Drosophila melanogaster Drak gene Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241001598113 Laminaria digitata Species 0.000 description 1
- 239000005717 Laminarin Substances 0.000 description 1
- 241001215120 Leptospirales Species 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027439 Metal poisoning Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241000543821 Oestrus Species 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039587 Scarlet Fever Diseases 0.000 description 1
- 241000522620 Scorpio Species 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 201000001028 acute contagious conjunctivitis Diseases 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000037006 agalactosis Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000496 anti-anoxic effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003471 anti-radiation Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 235000019621 digestibility Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000000009 lactational effect Effects 0.000 description 1
- DBTMGCOVALSLOR-VPNXCSTESA-N laminarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](O)C(O[C@H]2[C@@H]([C@@H](CO)OC(O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-VPNXCSTESA-N 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 208000008127 lead poisoning Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960005195 morphine hydrochloride Drugs 0.000 description 1
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000003726 plant lectin Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000009490 scorpio Substances 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- HUAUNKAZQWMVFY-UHFFFAOYSA-M sodium;oxocalcium;hydroxide Chemical compound [OH-].[Na+].[Ca]=O HUAUNKAZQWMVFY-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000012153 swine disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000006442 vascular tone Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940057613 veratrum Drugs 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P60/00—Technologies relating to agriculture, livestock or agroalimentary industries
- Y02P60/80—Food processing, e.g. use of renewable energies or variable speed drives in handling, conveying or stacking
- Y02P60/87—Re-use of by-products of food processing for fodder production
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种哺乳期母猪配合饲料及其制备方法,其配合饲料中各种原料为:小麦、东北玉米、46%豆粕、豆皮、磷酸氢钙、米糠油、液态植酸酶、液体复合酶、石粉、食盐、65%赖氨酸、苏氨酸、60%氯化胆碱、抗氧化剂、血浆蛋白粉、氯化钾、硫酸镁、维生素预混料和微量元素预混料;其制备方法包括:按重量百分比称取所有原料,投入粉碎机进行粉碎,粉碎粒度为25-40目;投入制粒机进行制粒,制粒温度为85℃,使其糊化度达到90%以上。本发明的有益效果是:满足了哺乳母猪的营养需求,适口性好,提高了母猪的免疫力、产奶量及奶水质量,进而提高了仔猪的生产性能。
Description
技术领域
本发明涉及喂养哺乳期母猪的配合饲料,特别涉及一种哺乳期母猪配合饲料及其制备方法。
背景技术
母猪饲养是养猪生产的重要环节之一,在生产实践中,如何提高母猪的生产性能是养猪生产的重点。母猪产仔数多、仔猪成活率高、延长母猪的利用一直是养猪工作者所追求的目标。哺乳期的母猪既要维持自己的生命需要,产后需要恢复产前的体况,又要泌乳供给仔猪,母猪抵抗力降低,容易患病不仅影响自身的产奶量和生产性能下降,而且还降低奶水的质量,影响仔猪后期的生长速度、仔猪活力、断奶重、拉稀率及成活率。除了遗传因素外,营养是影响母猪繁殖性能最主要的因素,因此在养猪生产高度集约化、规模化的今天对母猪的营养提出了更高的要求。作为饲料它必须具备可口性和营养性两个特征,通过饲喂哺乳期母猪用饲料,使哺乳期母猪能够获得充足的营养成分,迅速恢复健康并具有充足、高质量的奶水。
玉米一直是畜禽饲料的主要来源,因其工业用途的开发(如酒精、乙醇),除价格居高不下外,因其收割、贮存的粗放,其霉变率较高,特别是当处在高湿的环境下,其霉变会越来越严重,霉菌毒素是某些霉菌在基质上生长繁殖过程中产生的有毒二次代谢产物,霉变玉米一直是霉菌毒素的重要来源,河南玉米中6种霉菌毒素含量的检出率和超标率均较高,再加上猪对霉菌毒素十分敏感:玉米霉菌毒素能够破坏猪的免疫系统,造成猪病高发,特别是母猪的不发情、返情、不孕、死胎等80%都是由霉菌毒素引起的,玉米霉变后,其营养成分和利用率也随之降低,造成猪的营养不良、生长受阻,因玉米霉菌毒素给养猪场造成的效益损失达40%以上。在饲料中添加脱霉剂可吸附部分霉菌,但不能从根本上解决问题,并且市场上出售的脱霉剂鱼龙混杂,真假难辨,效果自然大打折扣。因此探寻一种可以替代普通玉米的常规原料,以降低玉米霉菌毒素的危害和饲料成本,具有重大的现实意义。
麦类资源以其种植面积广、产量高的特点成为替代玉米的首选。小麦的营养价值和玉米相比,其粗蛋白、 钙、 磷含量高,但代谢能和饲料利用率较低,且小麦中含有阿拉伯木聚糖、β-葡萄聚糖等非淀粉多糖(NSP)和粗纤维、胰蛋白酶抑制因子、植物凝集素及一些难于被消化的特殊结构蛋白质等抗营养因子,如果直接大量饲喂,不仅包裹营养物质,妨碍营养物质与消化酶间的相互作用,而且会引起畜禽机能性损伤,最终表现为降低营养物质利用率,抑制动物生长。
如何解决上述问题,则是本发明所面临的课题。
发明内容
为了满足哺乳期母猪的营养需求、提高母猪的生产性能、免疫力及产奶量,本发明实施例提供了一种哺乳期母猪配合饲料及其制备方法。
为了实现上述发明目的,本发明提供了一种哺乳期母猪配合饲料,所述配合饲料中原料包括:小麦、东北玉米、46%豆粕、豆皮、磷酸氢钙、米糠油、液态植酸酶、液体复合酶、石粉、食盐、65%赖氨酸、苏氨酸、60%氯化胆碱、抗氧化剂、血浆蛋白粉、氯化钾、硫酸镁、维生素预混料和微量元素预混料。
所述配合饲料还包括中药添加剂;所述配合饲料中各种原料及其重量百分比为:小麦45-56%、东北玉米16-25%、46%豆粕15-20%、豆皮4-7%、磷酸氢钙0.8-1.5%、米糠油0.7-1.3%、液态植酸酶0.01-0.03%、液体复合酶0.01-0.03%、石粉0.8-1.5%、食盐0.3-0.5%、65%赖氨酸0.4-0.6%、苏氨酸0.1-0.2%、60%氯化胆碱0.1-0.2%、抗氧化剂0.03-0.06%、血浆蛋白粉0.4-0.6%、氯化钾0.2-0.4%、硫酸镁0.1-0.3%、维生素预混料 0.2-0.3%、微量元素预混料 0.1-0.3%、中药添加剂0.05-0.1;上述原料的重量百分比之和为100%。
所述配合饲料中各种原料及其重量百分比优选为:小麦50%、东北玉米21.28%、46%豆粕17.6%、豆皮5%、磷酸氢钙1%、米糠油1%、液态植酸酶0.02%、液体复合酶0.02%、石粉1.3%、食盐0.4%、65%赖氨酸0.5%、苏氨酸0.15%、60%氯化胆碱0.15%、抗氧化剂0.05%、血浆蛋白粉0.5%、氯化钾0.3%、硫酸镁 0.2%、维生素预混料 0.25%、微量元素预混料0.2%、中药添加剂0.08。
所述中药添加剂中各种中药原料及其重量份数比为:黄芪12-27份、黄苓10-15份、红花9-15份、通草2-15份、通脱木2-15份、板蓝根7-12份、昆布9-15份。
所述中药添加剂中各种中药原料及其重量份数比优选为:黄芪20份、黄苓12份、红花10份、通草5份、通脱木8份、板蓝根9份、昆布12份。
所述中药添加剂的制备方法包括:按照重量份数比称取所有中药原料混合研磨成120-180目细粉,制备成所述中药添加剂,原料药的粉碎粒度为2-5mm,使其细粉量达到中药添加剂总量的 95%以上。
所述维生素预混料为维生素A、D3、E、K3、B1、B2、B6、叶酸、泛酸、烟酸中的一种或多种;所述微量元素预混料为铜、铁、锰、锌、碘、硒中的一种或多种。
所述维生素预混料优选为维生素A 12000IU/kg、维生素D3 2200IU/kg和/或维生素E 110IU/kg;所述微量元素预混料优选为铜 155mg/kg、铁 160mg/kg、锰 75mg/kg和锌 280mg/kg;
所述液体复合酶为木聚糖酶、纤维素酶和β-葡聚糖酶中的一种或多种。
所述血浆蛋白粉为APC美国蛋白质公司生产的进口血浆蛋白粉。
为了更好的实现上述发明目的,本发明还提供了一种哺乳期母猪配合饲料的制备方法,所述制备方法包括:
按重量百分比称取所有原料,投入粉碎机进行粉碎,粉碎粒度为25-40目;
投入制粒机进行制粒,制粒温度为85℃,使其糊化度达到90%以上。
所述粉碎粒度优选为30目。
本发明实施例提供的技术方案带来的有益效果是:满足了哺乳母猪的营养需求,适口性好,提高了母猪的免疫力、产奶量及奶水质量,进而提高了仔猪的生产性能;其中,添加血浆蛋白粉,为母猪提供免疫球蛋白,提高母猪的抗病力;添加液体小麦酶,提高了小麦的代谢能、饲料转化率以及干物质、脂肪和蛋白质的利用率,降低了哺乳母猪肠道内弃物的粘度和排泄物中的水分,改善肠道菌群状态,减少畜禽后肠道微生物的数量,消除了小麦中NSP的抗营养作用;精选籽粒饱满、容重高、无霉变的东北玉米,避免了霉菌毒素对母猪的极大危害;添加米糠油,保证母猪的足够能量供应,提高母猪的体储,减少泌乳期的体损失,提高母猪的生产性能;添加豆皮,有效的防止了母猪便秘和胃溃疡的发生;添加中药添加剂,不仅预防疾病,增强机体的免疫功能,而且能够提高营养物质的消化率、利用率,提高产奶量及恢复速度。
具体实施方式
针对传统猪饲料不能提高哺乳期母猪的抵抗力和产奶量,本发明实施例提供了一种哺乳期母猪配合饲料,其中各种原料及其重量百分比为:小麦50%、东北玉米21.28%、46%豆粕17.6%、豆皮5%、磷酸氢钙1%、米糠油1%、液态植酸酶0.02%、液体复合酶0.02%、石粉1.3%、食盐0.4%、65%赖氨酸0.5%、苏氨酸0.15%、60%氯化胆碱0.15%、抗氧化剂0.05%、血浆蛋白粉0.5%、氯化钾0.3%、硫酸镁 0.2%、维生素预混料 0.25%、微量元素预混料0.2%、中药添加剂0.08。
中药添加剂中各种中药原料及其重量份数比优选为:黄芪20份、黄苓12份、红花10份、通草5份、通脱木8份、板蓝根9份、昆布12份。
中药添加剂的制备方法包括:按照重量份数比称取所有中药原料混合研磨成120-180目细粉,制备成所述中药添加剂,原料药的粉碎粒度为2-5mm,使其细粉量达到中药添加剂总量的 95%以上。
其中,中药添加剂中各种中药性能介绍如下:
黄芪:甘,微温;归肺、脾、肝、肾经。 用于益气固表、敛汗固脱、托疮生肌、利水消肿之功效。《本草逢原》载:黄芪能补五脏诸虚,治脉弦自汗,泻阴火,去肺热,无汗则发,有汗则止。用于治疗气虚乏力,中气下陷,久泻脱肛,便血崩漏,表虚自汗,痈疽难溃,久溃不敛,血虚萎黄,内热消渴,慢性肾炎,蛋白尿,糖尿病等。炙黄芪益气补中,生用固表托疮。黄芪是增进抵抗力和防御疾病的良药。
黄苓:抗炎、抗变态反应作用;保肝利胆作用;降压、利尿、镇静、解热作用;醛糖还原酶抑制作用。临床主要用于传染性肝炎,急性胆道感染,铅中毒,清热解毒,胸闷呕恶,肺热咳嗽,肿瘤疮毒胎动不安。
红花:对心血管系统的作用:红花煎剂小剂量能使蟾蜍离体心脏及兔在体心脏轻度兴奋,使心跳有力,振幅加大;大剂量则对心脏有抑制作用,使心率减慢,心肌收缩力减弱,心搏出量减少。红花水提取物及红花水溶性混合物-红花黄色素有增加冠脉血流量及心肌营养性血流量的作用;而红花乙醇提取物的扩张冠脉及增加冠脉血流量的作用则不明显或无影响。 在兔、大鼠、犬等造成实验性心肌缺血或心肌梗塞的动物模型上,红花及其制剂均有不同程度的对抗作用。红花可使因垂体后叶素引起的大鼠或家兔急性心肌缺血有明显保护作用;可使反复短暂阻断冠状动脉血流造成麻醉犬急性心肌缺血的程度明显减轻,范围缩小,心率减慢,并保护急性心肌梗塞区的边缘,区而缩小梗塞范围及降低边缘区心电图ST段抬高的幅度,从而改善缺血心肌氧的供求关系。 如先用含微量肾上腺素或去甲肾上腺素的洛氏液灌流血管,使动物离体血管平滑肌收缩保持一定的血管紧张性,造成可能类似人的血脉不通、血瘀状态。红花可使紧张性增高的豚鼠后肢和兔耳呈现血管扩张作用,并随剂量增加而作用明显,红花亦可增加麻醉犬股动脉血流量,但对蟾蜍和兔的正常离体血管可使之收缩。表明红花扩张血管作用与血管的功能状态和药物的剂量有关。其作用机制可能主要是直接或部分对抗a-肾上腺素能受体的作用而使血管扩张,并有较弱的直接收缩血管作用。红花煎剂、红花黄色素及其他制剂对麻醉猫或犬均有不同程度的迅速降压作用,平均血压下降20毫米Hg左右,持续约30分钟后恢复。红花黄色素具有非常显著地抑制ADP诱导的家兔血小板聚集作用,并对ADP已聚集的血小板也有非常明显的解聚作用。当剂量为0.22g/ml时,聚集抑制率和解聚百分率分别达到85.9%和78.9%。红花黄色素的这些作用,随着剂量的增加而增强。红花黄色素对大鼠实验性血栓形成,有非常显著的抑制效应,其抑制率为73.4%。由于实验采用丝线上形成的血栓物质基础系血小板聚集物,因此血栓湿重的减轻,显然是药物抑制血小板聚集的结果。与体外实验所证实的红花黄色素能抑制ADP引起的血小板聚集作用是一致的。红花黄色素尚可明显延长家兔血浆复钙时间、凝血酶原时间和凝血时间。表明它能同时影响体内和体外的凝血系统。此外,红花油有降低血脂作用。对动物耐缺氧的影响:抗疲劳作用,红花黄色素1100mg/kg小鼠与对照组(用等量生理盐水)比较,游泳时间明显延长,延长率达117.O%,P<0.01。 ;小鼠ipll00mg/kg红花黄色素,与对照组(等容量生理盐水)比较,在给药30分钟后,每鼠分别放入盛有15g钠石灰的125ml密闭玻璃瓶中,实验组延长存活时间48.8%,P<0.01。对小鼠减压缺氧耐力的影响:同上法小鼠给药30分钟后,将小鼠分别放入容积相等的仓内,密闭减压至负压450mmHg,观察60分钟。结果与对照组比较,存活率(%)15:10,给药组延长存活时间168.72%,P<0.001。对子宫的作用: 红花煎剂对小鼠、豚鼠、兔与犬的离体子宫均有兴奋作用。麻醉动物实验表明,煎剂iv对小鼠、猫与犬的在位子宫也都有兴奋作用。无论离体或在位于宫给药后紧张性或(和)节律性明显增加,有时兴奋作用强烈,可引起痉挛。对已孕子宫的作用比未孕者更为明显。子宫瘘兔iv煎剂后亦出现子宫兴奋反应,收缩频率增加,幅度加大,作用较持久。亦有报道,在摘除卵巢小鼠的阴道周围注射红花煎剂,可使子宫重量明显增加,提示有雌激素样作用。镇痛和镇静作用:取小鼠40只,分4组。分别ip红花黄色素550mg/kg、1100mg/kg、盐酸吗啡20mg/kg及等容量生理盐水。30分钟后ip0.7%冰醋酸0.1ml/10g。观察每鼠在20分钟内扭体次数,与对照组比较,计算小鼠扭体反应抑制率。结果两种剂量的红花黄色素均能明显抑制小鼠扭体反应,P均<0.001。用上述两种剂量的组的小鼠,30分钟后各组动物ip巴比妥钠阈下催眠剂量300mg/kg或水合氯醛阈下催眠剂量250mg/kg。观察30分钟内翻正反射消失达l分钟以上的小鼠数,计算各组动物入睡率。结果表明,给巴比妥钠阈下剂量的对照动物均呈清醒状态,而与红花黄色素合用,大剂量的入睡率提高40%,大剂量提高70%(P<0.01);两种剂量可使水合氯醛阈下剂量入睡率由20%,分别提高50%和80%(P<0.01),提示红花黄色素有明显增强巴比妥及水合氯醛的中枢抑制作用,其作用与用量成平行关系。抗炎作用:红花黄色素对甲醛性足肿胀有明显抑制作用。对大鼠毛细血管通透性的影响:对组胺引起的大鼠皮肤毛细血管的通透量增加有明显的抑制作用。免疫活性: 红花多糖不同于高等植物中a-键连接的多糖,类似于细菌来源的多糖。从体外淋转实验表明,红花多糖与T细胞致有丝分裂原ConA有协同作用,对B细胞致有丝分裂原无明显影响。但体内PFC试验,红花多糖与一般认为作用于B细胞的黄芪多糖作用趋势一致。给小鼠注射红花多糖的时间不同,小鼠PFC值的变化也不同:致敏后给药组的PFC被促进,而致敏前给药组的PFC反被抑制。表明红花多糖同样显示了免疫药物的双向性。红花多糖能明显对抗强的松龙的免疫抑制作用,它对强的松龙抑制小鼠的免疫增强作用较对正常小鼠的作用更为明显。因此,红花多糖能促进淋已细胞转化,增加脾细胞对羊红细胞空斑形成的细胞数,对抗强的松龙的免疫抑制作用等,表明它是一种新的、值得进一步研究的免疫调节剂。另红花总黄素(SY)降低血清溶菌酶含量、腹腔巨噬细胞和全血白细胞吞噬功能;使PFC、SRFC和抗体产生减少;抑制DH反应和SOI诱导的Ts细胞活化,体外,SY0.03-3.0,0.1-2.O和0.1-2.5mg/ml抑制TdR掺入的T、B淋巴细胞转化、MLC反应、IL2的产生及其活性。
通草:通草性味与归经是:甘、淡、微寒,归肺、胃经,其功能与主治为:清热利尿、通气下乳,用于湿热尿赤、淋病涩痛、水肿尿少、乳汁不下。.《本草纲目》记载:通草,色白而气寒,味淡而体轻,故入太阴肺经,引热下降而利小便;入阳明胃经,通气上达而下乳汁;其气寒,降也,其味淡,开也。
通脱木:性味归经:味甘、淡、性微寒;归肺、胃经。 功效:清势利水;通乳 ,考证:出自《本草纲目拾遗》。 《本草拾遗》:通脱木,生山侧。叶似萆麻,心中有瓤,轻白可爱,女工取以饰物。《尔雅》云离南、活脱也。一本云药草,生江南,主虫病,今俗亦名通草。 《本草图经》:俗间所谓通草,乃通脱木也,今园圃间亦有种两者。古方所用通草,皆今之木通,通脱稀有使用者。近世医家多用利小便,南人或以蜜煎作果,食之甚美。 主治:淋症涩痛;小便不利;水肿;黄疸;湿温病;小便短赤;产后乳少;经闭;带下。
板蓝根:抗病原微生物作用:板蓝根对多种细菌有抑制作用。水浸液对枯草杆菌、金黄色葡萄球菌、八联球菌、大肠杆菌、伤寒杆菌、副伤寒杆菌、痢疾(志贺、弗氏)杆菌、肠炎杆菌等都有不同程度的抑制作用;丙酮浸出液也有类似作用, 且对溶血性链球菌有效(皆用琼脂小孔平板法)。对 A 型脑膜炎球菌之抑菌作用与大蒜、金银花相似.对流感病毒PR8 株和京科68-1株有明显抑制作用。在试管内板蓝根有杀灭钩端螺旋体的作用。对心血管的作用:该品能使离体兔耳和大鼠下肢灌流量增加,改善家兔肠系膜微循环, 降低麻醉家兔的血压,减少毛细血管通透性, 并使小鼠心肌耗氧量下降。抑制血小板聚集作用 板蓝根对ADP诱导的家兔血小板聚集有显著抑制作用。从板蓝根中分得尿苷、次黄嘌呤、嘧啶、水杨酸等对ATP诱导的家兔血小板聚集也都表现一定的抑制活性,在0.21mg/kg浓度时其抑制率分别为18.2%、24.2%、10.8%和20%。解毒作用:犬用板蓝根、黄连粉与藜芦同服(各2.0g/kg),能解藜芦毒,降低死亡率;若藜芦中毒后再用之,则无效;分别单用板蓝根粉或黄连粉,效果亦不好。《本草述》:苦,寒,无毒。 《本草便读》:入肝、胃血分。 《中华本草》:归肝;胃经。具有清热、解毒、凉血、利咽功效。治疗温毒发斑;高热头痛;大头瘟疫;舌绛紫暗,烂喉丹痧;丹毒;痄腮;喉痹;疮肿、痈肿;水痘;麻疹;肝炎;流行性感冒,流脑,乙脑,肺炎,神昏吐衄,咽肿,火眼,疮疹;可防治流行性乙型脑炎、急慢性肝炎、流行性腮腺炎、骨髓炎。
昆布:具有降压、降血糖、降血脂、抗凝作用和抗放射作用,其他作用:海藻昆布流浸膏对感染血吸虫尾蚴的家兔,有保护作用(煎剂无效)。以流浸膏2g/kg在感染后1天开始口服,连续90天,则兔体内血吸虫虫体余存数较对照组显著减少,特别是肝脏病变远较对照组为轻微,正常结构大致保存,仅见少量虫卵结节形成,周围纤维化不显著,尤其是新生虫卵很难找到。小鼠口服海藻、昆布及全蝎、蜈蚣等之复方(化癌丹)煎剂,对艾氏腹水癌有抑制作用。昆布素对大鼠的网状肉瘤IRE(腹水型)则并无影响。从L.Cloustoni中提得的硫酸昆布素M,静脉注射(人)后清除血脂、增加脂蛋白之电泳能力、改变脂蛋白之分布情况皆与肝素相似,唯持续时间较短(4-6小时)。肌肉注射(100mg)效果不显著,可能由于剂量不够。昆布中含有的藻胶酸钠,对动物股动脉之出血,据云有止血作用。
中药添加剂的制备方法包括:按照重量百分比称取所有中药原料混合研磨成120-180目细粉,制备成所述中药添加剂,原料药的粉碎粒度为2-5mm,使其细粉量达到中药添加剂总量的 95%以上。
维生素预混料为维生素A 12000IU/kg、维生素D3 2200IU/kg和/或维生素E 110IU/kg;所述微量元素预混料为铜 155mg/kg、铁 160mg/kg、锰 75mg/kg和锌 280mg/kg;液体复合酶为木聚糖酶、纤维素酶和β-葡聚糖酶中的一种或多种;血浆蛋白粉为APC美国蛋白质公司生产的进口血浆蛋白粉。
同时还提供了一种哺乳期母猪配合饲料的制备方法,其制备方法包括:
按重量百分比称取所有原料,投入粉碎机进行粉碎,粉碎粒度为30目;
投入制粒机进行制粒,制粒温度为85℃,使其糊化度达到90%以上。
按照上述重量百分比和制备方法得到的本发明母猪饲料,经实验分析,其营养成分的保证值是:粗蛋白≥16.0%、粗脂肪≥2.0%、粗纤维≤10.0%、粗灰分≤9.0%、水分≤14.0%、钙0.5%-1.50%、总磷≥0.45%、盐0.3-0.8%、蛋氨酸≥0.3%、苏氨酸≥0.6%。
对比实验:
将本发明实施例的母猪饲料(实施例组)和传统的猪饲料(对照组),分别喂养100头刚产下仔猪的母猪进行对比实验,每只母猪喂养至下次发情为止,实验过程记录泌乳期母猪的背膘减少情况及断奶至下次发情时间间隔,并记录仔猪初重及断奶体重,计算出平均日增重及成活率,结果如表1和表2所示:
表1:母猪断奶前背膘减少量和断奶至下次发情时间间隔
从表1的数据可知:使用本发明实施例的猪饲料喂养的哺乳期母猪,其泌乳期P2点背膘减少量比传统饲料喂养的母猪低1.29mm,断奶至下次发情时间间隔低1.35天。
表2:母猪产仔数及断奶仔猪增重的对照表
从表2的数据可知:使用本发明实施例的猪饲料喂养的哺乳期母猪,其奶水喂养的仔猪平均日增重比传统饲料高出11g/d,其成活率高出8%;实施例组的窝平总产仔数、窝平活产仔数、窝平合格仔数均高于对照组,仔猪初生重和日增重由于产仔数较多而略低于对照组,但是断奶窝平均日增重却高于对照组。
通过对比实验可知,本发明实施例配比的母猪饲料喂养的哺乳期母猪背膘减少量和发情间隔时间均优于传统母猪饲料,其产下仔猪的数量、合格率及断奶仔猪平均日增重均优于传统母猪饲料喂养母猪产下的仔猪,且实施例组的整齐度也明显优于对照组,即本发明实施例的配合饲料能够很好地满足哺乳期母猪的营养需求,提高了母猪的生产性能,还促使母猪断奶后尽快发情,以便尽快配种转入下一个繁殖周期,且产下仔猪的生产性能非常优越,表明本发明实施例的配合饲料还提高了母猪的奶水量和奶水质量。
以上所述仅为本发明的较佳实施例,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (6)
1.一种哺乳期母猪配合饲料,其特征在于,所述配合饲料中各种原料及其重量百分比为:小麦45-56%、东北玉米16-25%、46%豆粕15-20%、豆皮4-7%、磷酸氢钙0.8-1.5%、米糠油0.7-1.3%、液态植酸酶0.01-0.03%、液体复合酶0.01-0.03%、石粉0.8-1.5%、食盐0.3-0.5%、65%赖氨酸0.4-0.6%、苏氨酸0.1-0.2%、60%氯化胆碱0.1-0.2%、抗氧化剂0.03-0.06%、血浆蛋白粉0.4-0.6%、氯化钾0.2-0.4%、硫酸镁0.1-0.3%、维生素预混料 0.2-0.3%、微量元素预混料 0.1-0.3%、中药添加剂0.05-0.1%;上述原料的重量百分比之和为100%;
所述中药添加剂中各种中药原料及其重量份数为:黄芪12-27份、黄苓10-15份、红花9-15份、通草2-15份、通脱木2-15份、板蓝根7-12份、昆布9-15份;
所述液体复合酶为木聚糖酶、纤维素酶和β-葡聚糖酶中的多种。
2.根据权利要求1所述的哺乳期母猪配合饲料,其特征在于,所述配合饲料中各种原料及其重量百分比为:小麦50%、东北玉米21.28%、46%豆粕17.6%、豆皮5%、磷酸氢钙1%、米糠油1%、液态植酸酶0.02%、液体复合酶0.02%、石粉1.3%、食盐0.4%、65%赖氨酸0.5%、苏氨酸0.15%、60%氯化胆碱0.15%、抗氧化剂0.05%、血浆蛋白粉0.5%、氯化钾0.3%、硫酸镁 0.2%、维生素预混料 0.25%、微量元素预混料0.2%、中药添加剂0.08%。
3.根据权利要求1或2所述的哺乳期母猪配合饲料,其特征在于,所述维生素预混料为维生素A、D3、E、K3、B1、B2、B6、叶酸、泛酸、烟酸中的一种或多种;所述微量元素预混料为铜、铁、锰、锌、碘、硒中的一种或多种。
4.根据权利要求1或2所述的哺乳期母猪配合饲料,其特征在于,所述血浆蛋白粉为APC美国蛋白质公司生产的进口血浆蛋白粉。
5.一种如权利要求1-4任一所述哺乳期母猪配合饲料的制备方法,其特征在于,所述制备方法包括:
按重量百分比称取所有原料,投入粉碎机进行粉碎,粉碎粒度为25-40目;
投入制粒机进行制粒,制粒温度为85℃,使其糊化度达到90%以上。
6.根据权利要求5所述的哺乳期母猪配合饲料的制备方法,其特征在于,所述粉碎粒度为30目。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012102775284A CN102763784B (zh) | 2012-08-07 | 2012-08-07 | 一种哺乳期母猪配合饲料及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012102775284A CN102763784B (zh) | 2012-08-07 | 2012-08-07 | 一种哺乳期母猪配合饲料及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102763784A CN102763784A (zh) | 2012-11-07 |
CN102763784B true CN102763784B (zh) | 2013-07-10 |
Family
ID=47091547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2012102775284A Expired - Fee Related CN102763784B (zh) | 2012-08-07 | 2012-08-07 | 一种哺乳期母猪配合饲料及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102763784B (zh) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102987143A (zh) * | 2012-11-29 | 2013-03-27 | 遵义市金鼎农业科技有限公司 | 一种泌乳母猪全价饲料 |
CN103053852B (zh) * | 2013-01-23 | 2014-06-04 | 郑州宏展饲料添加剂有限公司 | 一种哺乳母猪6%预混料及使用该预混料配制成的小麦型日粮 |
CN103262942B (zh) * | 2013-05-23 | 2014-06-25 | 山东省农业科学院畜牧兽医研究所 | 一种母猪用小麦胚芽饲料及其制备方法 |
CN103355531A (zh) * | 2013-07-16 | 2013-10-23 | 江苏华威农牧发展有限公司 | 母猪怀孕后期及哺乳期生物饲料 |
CN103583927B (zh) * | 2013-11-28 | 2014-12-10 | 淮安正昌饲料有限公司 | 一种提高母猪生产性能的后备母猪配合饲料及其制备方法 |
CN103609853B (zh) * | 2013-12-12 | 2015-01-07 | 山东新希望六和集团有限公司 | 用于治疗猪胃溃疡的饲料及其制备方法 |
CN103843994B (zh) * | 2014-03-21 | 2015-08-12 | 安徽泗县成安牧业科技有限公司 | 一种防治仔猪断奶应急综合症的饲料及其制备方法 |
CN103976194A (zh) * | 2014-06-06 | 2014-08-13 | 唐人神集团股份有限公司 | 一种高效环保型哺乳母猪配合饲料及其制备方法 |
CN104187050A (zh) * | 2014-07-23 | 2014-12-10 | 合肥德美畜牧技术有限公司 | 一种具有保健作用的复合猪饲料 |
CN104206930A (zh) * | 2014-09-30 | 2014-12-17 | 梁翠 | 一种抗腹泻的猪饲料 |
CN104472948A (zh) * | 2014-12-17 | 2015-04-01 | 通威股份有限公司 | 一种全小麦妊娠母猪日粮及其配制方法 |
CN104543491A (zh) * | 2014-12-19 | 2015-04-29 | 广西师范大学 | 一种哺乳期母竹鼠精料混合颗粒料及其制备方法 |
CN104970220A (zh) * | 2015-06-11 | 2015-10-14 | 山东新希望六和集团有限公司 | 一种哺乳期母猪配合饲料及其制备方法 |
CN104957367A (zh) * | 2015-06-29 | 2015-10-07 | 曾少兰 | 一种哺乳期母猪饲料 |
CN105053650A (zh) * | 2015-08-07 | 2015-11-18 | 唐必芳 | 一种哺乳母猪饲料及其制备方法 |
CN105901292A (zh) * | 2016-04-25 | 2016-08-31 | 安徽和盛伟业饲料有限公司 | 一种10%高能量母猪哺乳期复合预混料 |
CN105901369A (zh) * | 2016-04-25 | 2016-08-31 | 安徽和盛伟业饲料有限公司 | 一种母猪哺乳期复合预混料 |
CN106107103A (zh) * | 2016-06-14 | 2016-11-16 | 曲靖友美动物食品有限公司 | 一种哺乳母猪配合饲料 |
CN106306472A (zh) * | 2016-08-23 | 2017-01-11 | 靖西市家宝贸易有限公司 | 一种哺乳期母猪饲料及其制备方法 |
CN107373050A (zh) * | 2017-07-20 | 2017-11-24 | 贵阳富源饲料有限公司 | 一种促情优配母猪配合饲料及其制备方法 |
CN109619304A (zh) * | 2019-01-28 | 2019-04-16 | 山东新希望六和集团有限公司 | 一种哺乳期母猪饲料添加剂、制备方法及其应用 |
CN111053789A (zh) * | 2019-11-26 | 2020-04-24 | 湖南营养树生物科技有限公司 | 调节免疫系统的方法和组合物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102048036A (zh) * | 2009-11-05 | 2011-05-11 | 苏州海精灵实业有限公司 | 一种怀孕母猪饲料 |
CN101999545A (zh) * | 2010-12-01 | 2011-04-06 | 北京资源亚太饲料科技有限公司 | 一种哺乳母猪配合饲料及其制备方法 |
-
2012
- 2012-08-07 CN CN2012102775284A patent/CN102763784B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN102763784A (zh) | 2012-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102763784B (zh) | 一种哺乳期母猪配合饲料及其制备方法 | |
CN103355552B (zh) | 一种鲤鱼鱼种期配合饲料及其制备方法 | |
CN103141709B (zh) | 一种鲤鱼饲料及其制备方法 | |
CN103141710B (zh) | 一种断奶仔猪配合饲料及其制备方法 | |
CN103156095B (zh) | 一种肉雏鸡配合饲料及其制备方法 | |
CN102940157B (zh) | 用于提高草鱼抗病能力的中药饲料添加剂 | |
CN102669495B (zh) | 一种小麦型仔猪14-35日龄配合饲料及其制备方法 | |
CN102940155B (zh) | 一种樱桃谷鸭的雏鸭饲料及其制备方法 | |
CN103478508B (zh) | 用于提高鸡免疫力的中药组合物、饲料及其制备方法 | |
CN103238756A (zh) | 一种育肥猪配合饲料及其制备方法 | |
CN103719609B (zh) | 一种哺乳期母猪饲料及其制备方法 | |
CN102488848A (zh) | 治疗高致病性猪蓝耳病的中药组合物、制备方法和应用 | |
CN105379973A (zh) | 一种山羊饲料 | |
CN105685476A (zh) | 一种石斑鱼饲料及其制备方法 | |
CN102754754A (zh) | 一种全燕麦型仔猪配合饲料及其制备方法 | |
CN103285145B (zh) | 一种促进猪快速生长的纯中药制剂及制备方法和使用方法 | |
CN102885201B (zh) | 一种复方中草药饲料添加剂 | |
CN105146228A (zh) | 用于母猪保胎的中药复方制剂及其制备方法 | |
CN110664896B (zh) | 一种抗应激防猝死的复方发酵中药添加剂及其制备方法和应用 | |
CN103404725A (zh) | 一种小麦型18-46日龄小猪饲料及其制备方法 | |
CN104982756A (zh) | 一种小麦次粉型小猪饲料及其制备方法 | |
CN108522888A (zh) | 一种促雏鸡生长、提高蛋鸡产蛋率的饲料及其制备方法 | |
CN108464406A (zh) | 促进肉鸡生长、改善肉质风味的肉鸡饲料及其制备方法 | |
CN108419750A (zh) | 一种降低兔球虫病发病率的养殖方法 | |
CN107373192A (zh) | 一种改善鲫鱼肉质用饲料 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130710 |